1-20 of 152
Musa Yilmaz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia

Free
Hannah Goulart, Hagop M. Kantarjian, Naval Daver, Musa Yilmaz, Guillermo Garcia-Manero, Kelly S. Chien, Jan A. Burger, Naveen Pemmaraju, Courtney D. DiNardo, Nicholas J. Short, Guillermo Montalban-Bravo, Abhishek Maiti, Danielle Hammond, Ghayas C. Issa, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia
Journal: Blood
Blood (2024) 144 (Supplement 1): 2901.
https://doi.org/10.1182/blood-2024-205340
Published: 2024
Journal Articles

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

Free
Alexandre Bazinet, Guillermo Garcia-Manero, Alex Bataller, Yesid Alvarado Valero, Musa Yilmaz, Elias Jabbour, Guillermo Montalban-Bravo, Naveen Pemmaraju, Ghayas C. Issa, Nicholas J. Short, Tapan M. Kadia, Nitin Jain, Lucia Masarova, Naval Daver, Danielle Hammond, Gautam Borthakur, Abhishek Maiti, Koichi Takahashi, Kelly S. Chien, Steven M. Kornblau, Hussein A. Abbas, Maro Ohanian, Jayastu Senapati, Courtney D. DiNardo, Hagop M. Kantarjian, Farhad Ravandi
Journal: Blood
Blood (2024) 144 (Supplement 1): 2896.
https://doi.org/10.1182/blood-2024-198541
Published: 2024
Journal Articles

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

Free
Jennifer Marvin-Peek, Himachandana Atluri, Nicholas J. Short, Abhishek Maiti, Koichi Takahashi, Sanam Loghavi, Curtis A Lachowiez, Yesid Alvarado Valero, Guillermo Montalban-Bravo, Koji Sasaki, Fadi G. Haddad, Ghayas C. Issa, Lucia Masarova, Hussein A. Abbas, Michael Andreeff, Gautam Borthakur, Jillian Mullin, George Donovan Tippett, Kelly S. Chien, Danielle Hammond, Jo Ishizawa, Nitin Jain, Patrick K. Reville, Mahesh Swaminathan, Musa Yilmaz, Naval Daver, Tapan M. Kadia, Farhad Ravandi, Guillermo Garcia-Manero, Hagop M. Kantarjian, Courtney D. DiNardo
Journal: Blood
Blood (2024) 144 (Supplement 1): 2883.
https://doi.org/10.1182/blood-2024-200387
Published: 2024
Journal Articles

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

Free
Courtney D. DiNardo, Kelly S. Chien, Jillian Mullin, Danielle Hammond, Jeremy Ramdial, Tapan M. Kadia, Fadi G. Haddad, Musa Yilmaz, Koji Sasaki, Ghayas C. Issa, Koichi Takahashi, Elizabeth J. Shpall, Farhad Ravandi, Naval Daver, Hagop Kantarjian
Journal: Blood
Blood (2024) 144 (Supplement 1): 1527.2.
https://doi.org/10.1182/blood-2024-208771
Published: 2024
Journal Articles

A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Trial in Progress

Free
Nicholas J. Short, Farhad Ravandi, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Musa Yilmaz, Ghayas C. Issa, Regina Abramova, Araceli Isabella Garza, Hagop M. Kantarjian, Hussein A. Abbas
Journal: Blood
Blood (2024) 144 (Supplement 1): 4288.1.
https://doi.org/10.1182/blood-2024-200923
Published: 2024
Journal Articles

Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3 -Tyrosine Kinase Domain (TKD) Mutations

Free
Sankalp Arora, Musa Yilmaz, Wei-Ying Jen, Nicholas J. Short, Sanam Loghavi, Tapan M. Kadia, Courtney D. DiNardo, Gautam Borthakur, Indraneel Deshmukh, Ghayas C. Issa, Joseph E. Jabbour, Naveen Pemmaraju, Michael Andreeff, Koichi Takahashi, Kapil N. Bhalla, Hussein A. Abbas, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Naval Daver
Journal: Blood
Blood (2024) 144 (Supplement 1): 841.
https://doi.org/10.1182/blood-2024-204042
Published: 2024
Journal Articles

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Free
Ian M. Bouligny, Hagop M. Kantarjian, Musa Yilmaz, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Guillermo Montalban-Bravo, Nicholas J. Short, Yesid Alvarado Valero, Nitin Jain, Naveen Pemmaraju, Danielle Hammond, Kelly S. Chien, Koichi Takahashi, Ghayas C. Issa, Hussein A. Abbas, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia
Journal: Blood
Blood (2024) 144 (Supplement 1): 446.
https://doi.org/10.1182/blood-2024-203938
Published: 2024
Journal Articles

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Free
Sankalp Arora, Jayastu Senapati, Sanam Loghavi, Patrick K. Reville, Bofei Wang, Tapan M. Kadia, Courtney D. DiNardo, Naveen Pemmaraju, Musa Yilmaz, Joseph E. Jabbour, Nicholas J. Short, Guillermo Montalban-Bravo, Abhishek Maiti, Guilin Tang, Koji Sasaki, Gautam Borthakur, Joie Alvarez, Sherry Pierce, Graciela M. Nogueras González, Jing Ning, Ghayas C. Issa, Michael Andreeff, Farhad Ravandi, Guillermo Garcia-Manero, Hussein A. Abbas, Naval Daver
Journal: Blood
Blood (2024) 144 (Supplement 1): 735.
https://doi.org/10.1182/blood-2024-203706
Published: 2024
Journal Articles

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Free
Ian M. Bouligny, Hagop M. Kantarjian, Musa Yilmaz, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Guillermo Montalban-Bravo, Nicholas J. Short, Yesid Alvarado Valero, Elias Jabbour, Nitin Jain, Naveen Pemmaraju, Danielle Hammond, Kelly S. Chien, Koichi Takahashi, Ghayas C. Issa, Hussein A. Abbas, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia
Journal: Blood
Blood (2024) 144 (Supplement 1): 734.
https://doi.org/10.1182/blood-2024-203459
Published: 2024
Journal Articles

Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML

Free
Aziz Farhat, Hagop M. Kantarjian, Koji Sasaki, Nicholas J. Short, Branko Cuglievan, Sanam Loghavi, Keyur P. Patel, Alex Bataller, Musa Yilmaz, Guillermo Montalban-Bravo, Danielle Hammond, Naveen Pemmaraju, Naval Daver, Farhad Ravandi, Elias Jabbour, Tapan M. Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Courtney D. DiNardo, Ghayas C. Issa
Journal: Blood
Blood (2024) 144 (Supplement 1): 2853.
https://doi.org/10.1182/blood-2024-205504
Published: 2024
Journal Articles

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

Free
Jennifer Marvin-Peek, Wei-Ying Jen, Nicholas J. Short, Ghayas C. Issa, Musa Yilmaz, Guillermo Montalban-Bravo, Alexandre Bazinet, Koji Sasaki, Abhishek Maiti, Gautam Borthakur, Danielle Hammond, Kelly S. Chien, Hussein A. Abbas, Naveen Pemmaraju, Guillermo Garcia-Manero, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo
Journal: Blood
Blood (2024) 144 (Supplement 1): 2851.
https://doi.org/10.1182/blood-2024-202429
Published: 2024
Journal Articles

A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Free
Jan A. Burger, Ekaterina Kim, Gitanjali Jayachandran, Wanda Lopez, Ghayas C. Issa, Musa Yilmaz, Mahesh Swaminathan, Jo Ishizawa, Alexandre Bazinet, Yesid Alvarado Valero, Nitin Jain, William G. Wierda, Alessandra Ferrajoli
Journal: Blood
Blood (2024) 144 (Supplement 1): 1868.
https://doi.org/10.1182/blood-2024-200331
Published: 2024
Journal Articles

Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3 -Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor

Free
Nicholas J. Short, Sanam Loghavi, Musa Yilmaz, Omer Karrar, Joseph E. Jabbour, Courtney D. DiNardo, Tapan M. Kadia, Gautam Borthakur, Ghayas C. Issa, Hussein A. Abbas, Marina Konopleva, Farhad Ravandi, Hagop M. Kantarjian, Naval Daver
Journal: Blood
Blood (2024) 144 (Supplement 1): 220.
https://doi.org/10.1182/blood-2024-210891
Published: 2024
Journal Articles

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Free
Ghayas C. Issa, Branko Cuglievan, Naval Daver, Courtney D. DiNardo, Aziz Farhat, Nicholas J. Short, David McCall, Allison Pike, Sheila Tan, Brianna Kammerer, Aimee Marshal, Musa Yilmaz, Tapan M. Kadia, Naveen Pemmaraju, Maro Ohanian, Hussein A. Abbas, Abhishek Maiti, Alexandre Bazinet, Elias Jabbour, Koji Sasaki, Gautam Borthakur, Guillermo Montalban-Bravo, Nitin Jain, Yesid Alvarado Valero, Farhad Ravandi, Guillermo Garcia-Manero, Michael Andreeff, Hagop M. Kantarjian
Journal: Blood
Blood (2024) 144 (Supplement 1): 216.
https://doi.org/10.1182/blood-2024-204375
Published: 2024
Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Free
Nitin Jain, Alessandra Ferrajoli, Mahesh Swaminathan, Patrick K. Reville, Jan A. Burger, Vanthana Bharathi, Himachandana Atluri, Hua-Jay J Cherng, Alex Bataller, Elias Jabbour, Tapan M. Kadia, Gautam Borthakur, Koichi Takahashi, Kelly S. Chien, Musa Yilmaz, Naveen Pemmaraju, Naval Daver, Fadi G. Haddad, Yesid Alvarado Valero, Jo Ishizawa, Guillermo Montalban-Bravo, Naveen Garg, Hyunsoo Hwang, Wei Qiao, Cameron Garcia, Anna Evangelio, Ana Ayala, Deepa Sampath, Varsha Gandhi, Michael J. Keating, Hagop M. Kantarjian, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 1011.
https://doi.org/10.1182/blood-2024-211454
Published: 2024
Journal Articles

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Free
Daniel Nguyen, Farhad Ravandi, Sa A. Wang, Jeffrey L. Jorgensen, Wei WANG, Sanam Loghavi, Jaehyun Lee, Pavan Bachireddy, Courtney D. DiNardo, Kelly S. Chien, Guillermo Montalban-Bravo, Ghayas C. Issa, Abhishek Maiti, Yesid Alvarado Valero, Naval Daver, Elias Jabbour, Tapan M. Kadia, Naveen Pemmaraju, Musa Yilmaz, Danielle T Nguyen, Uday Popat, Elizabeth J. Shpall, Guillermo Garcia-Manero, Hagop Kantarjian, Nicholas J. Short
Journal: Blood
Blood (2024) 144 (Supplement 1): 1007.
https://doi.org/10.1182/blood-2024-208684
Published: 2024
Journal Articles

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Free
Mahesh Swaminathan, Philip A. Thompson, Jan A. Burger, Musa Yilmaz, Nitin Jain, Tapan M. Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Alessandra Ferrajoli, Ghayas C. Issa, Steven M. Kornblau, Farhad Ravandi, Koji Sasaki, Gautam Borthakur, Kelly S. Chien, Courtney D. DiNardo, Danielle Hammond, Elias Jabbour, Guillermo Montalban-Bravo, Naveen Pemmaraju, Nicholas J. Short, Koichi Takahashi, Francesco Paolo Tambaro, Wei Qiao, Naveen Garg, Michael J. Keating, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 1855.
https://doi.org/10.1182/blood-2024-211110
Published: 2024
Journal Articles

Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia

Free
Daniel Nguyen, Hagop Kantarjian, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Musa Yilmaz, Alessandra Ferrajoli, Tapan M. Kadia, Yesid Alvarado Valero, Abhishek Maiti, Marianne Zoghbi, Jayastu Senapati, Rebecca Garris, Min Zhao, Marina Konopleva, Farhad Ravandi, Elias Jabbour
Journal: Blood
Blood (2024) 144 (Supplement 1): 1439.
https://doi.org/10.1182/blood-2024-208854
Published: 2024
Journal Articles

Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy

Free
Jayastu Senapati, Courtney D. DiNardo, Tapan M. Kadia, Niranjan Shiwaji Khaire, Fadi G. Haddad, Sanam Loghavi, Guilin Tang, Indraneel Deshmukh, Joseph E. Jabbour, Ghayas C. Issa, Nicholas J. Short, Musa Yilmaz, Danielle Hammond, Gautam Borthakur, Hussein A. Abbas, Alexandre Bazinet, Sherry Pierce, Kapil N. Bhalla, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Naval Daver
Journal: Blood
Blood (2024) 144 (Supplement 1): 4306.
https://doi.org/10.1182/blood-2024-208602
Published: 2024
Journal Articles

Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission

Free
Alexandre Bazinet, Naval Daver, Farhad Ravandi, Nicholas J. Short, Musa Yilmaz, Maro Ohanian, Jo Ishizawa, Abhishek Maiti, Courtney D. DiNardo, Lucia Masarova, William G. Wierda, Kelly S. Chien, Elias Jabbour, Danielle Hammond, Fadi G. Haddad, Koji Sasaki, Alex Bataller, Debra Bull-Linderman, Gautam Borthakur, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia
Journal: Blood
Blood (2024) 144 (Supplement 1): 4277.
https://doi.org/10.1182/blood-2024-198928
Published: 2024